title: J-LEAPS peptide and LEAPS dendritic cell vaccines.
abstract: The J-LEAPS vaccines contain a peptide from β-2-microglobulin covalently attached to disease-related peptides of 8-30 amino acids which contain a T cell epitope. The J-LEAPS vaccines can initiate a protective Th1 immune response or modulate an ongoing Th17 autoimmune response to the peptide. J-LEAPS vaccines activate and direct the nature of the subsequent immune response by promoting the maturation of precursor cells into a unique type of dendritic cell that produces interleukin 12, but not IL-1 or tumour necrosis factor, and presents the antigenic peptide to T cells. Adoptive transfer of JgD-LEAPS dendritic cells, matured with an anti-HSV-1 vaccine, promoted antigen-specific Th1 protection against lethal challenge with the virus. J-LEAPS peptide immunogens and J-LEAPS dendritic cell vaccines have potential applications for antimicrobial prevention and therapy, treatment of autoimmune diseases, and for cancer immunotherapy.
authors: Northeastern Ohio Medical University, Rootstown, OH, USA. ksr@neoucom.edu
authors: Ken S
authors: KS
authors: Rosenthal
authors: Patricia
authors: P
authors: Taylor
authors: Daniel H
authors: DH
authors: Zimmerman
mesh_terms: D000941:Antigens / Q000235:genetics / Q000276:immunology*; D001327:Autoimmune Diseases / Q000628:therapy; D003140:Communicable Disease Control / Q000379:methods; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D001613:beta 2-Microglobulin / Q000235:genetics / Q000276:immunology*
chemical_list: D000941:Antigens; D011993:Recombinant Fusion Proteins; D001613:beta 2-Microglobulin